Year: 2018
Type: article
Abstract: Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma, comprising 6–8% of human B-cell non-Hodgkin lymphomas 1 . R-CHOP, which combines rituximab with cyclophosphamide, hydroxydaunorubicin (Doxorubicin/Adriamycin), oncovin (Vincristine) and prednisone, is the most common regimen employed for treating MCL. Nevertheless, most patients are destined to relapse after initial therapy 2 , highlighting the urgent need for new therapeutic strategies. Here, we explore a member of Rac family of small guanosine triphosphatases (GTPase), Rac1, as novel target for MCL treatment.
Source: Blood Cancer Journal
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,290
OpenAlex ID: W2793084967